WuXi Biologics and its partner Pall Corp., a provider of advanced filtration, separation and purification technologies, established a joint lab to develop full continuous processing for the manufacture of monoclonal antibodies (mAb). The three-year project started with the continuous operation of individual processes and will gradually be expanded to downstream processing development and production. The joint lab will serve WuXi Biologics’ customers and aims to significantly reduce mAb dru...